Tepotinib PK in Hepatic Impairment

Phase 1, open-label trial of tepotinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by EMD Serono. Primary endpoints: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity, Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration and 1 more. Started Jun 2018; status: completed.